KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2025)

GoodRx Holdings' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $23.1 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 21.21% year-over-year to $23.1 million; the TTM value through Dec 2025 reached $85.2 million, up 22.55%, while the annual FY2025 figure was $85.2 million, 22.55% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $23.1 million at GoodRx Holdings, up from $21.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $33.0 million in Q3 2023 and bottomed at $5.4 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $15.9 million (2024), against an average of $16.2 million.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 141.78% in 2021 before it crashed 46.9% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $10.6 million in 2021, then skyrocketed by 45.88% to $15.5 million in 2022, then soared by 112.61% to $33.0 million in 2023, then tumbled by 42.18% to $19.1 million in 2024, then grew by 21.21% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Depreciation & Amortization (CF) are $23.1 million (Q4 2025), $21.4 million (Q3 2025), and $19.7 million (Q2 2025).